HMOX1 and neoplasm: To prove cytoprotective properties of HO-1 to anticancer treatment, the HO-1 inductor CoPP and ZnPP, which has been shown to inhibit HO-1 activity in vitro and in vivo [7,19-21], were added to tumor cells 24 h prior to the application of gemcitabine.